RESEARCH / PARTICIPATIONBack to the library
← Find a study
Completed · registry status

Exercise for Cognitive Excellence in Parkinson's Disease

A plain-language introduction is being prepared for this study. Open it to read the original description, who can join and how to contact the team.

Testing a treatment or activity · Study reference: NCT05720468

The registry title is shown while an English plain-language introduction is prepared. Read the original details below ↓

Open the official registry record ↗

Follow this study

Completed; watching for results

Start (reported actual date)
2023-07-20
Main measurements finished (reported actual date)
2026-05-06
Study finished (reported actual date)
2026-05-06

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — completed

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

Home-Based, Virtually Supervised Combined Exercise Intervention in People With Parkinson Disease: Protocol for a Randomized Controlled Trial.
Listed by the registry as research derived from the study · 2026

Participation rules recorded for this study

Ages 40 years to 80 years · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: 1. Diagnosis of idiopathic Parkinson's disease (PD) based on MDS criteria, with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity), without any other known or suspected cause of parkinsonism. 2. Modified Hoehn and Yahr stage less than 4 3. Age 40-80 years at time of screening 4. If being treated with PD symptomatic medications (i.e.g., rasagiline, carbidopa/levodopa, dopamine agonists, amantadine, anti-cholinergics), stable doses for greater than or equal to 2 months prior to baseline. If not being treated with PD symptomatic medication at time of screening, deemed unlikely to require symptomatic medication for next 6 months. Exclusion Criteria: 1. A diagnosis of atypical parkinsonism, drug-induced parkinsonism, essential tremor, primary dystonia or other diagnoses that explain symptoms other than PD. 2. A diagnosis of a significant neurological disease other than PD that would interfere with ability to perform study procedures or assessments. 3. Significant cognitive impairment defined as Montreal Cognitive Assessment (MoCA)\<23 or any impairment that would, in the opinion of the investigator, interfere with ability to follow exercise directions. 4. Beck Depression Inventory II (BDI) score \> 16, indicating depression that precludes ability to exercise. 5. Use of neuroleptics/dopamine receptor blockers for more than 30 days in the year prior to baseline visit, or any use within 30 days of baseline visit. 6. Recent use of psychotropic medications (e.g., recent use of psychotropic medications (i.e., anxiolytics, hypnotics, benzodiazepines, antidepressants) where dosage has not been stable for more than 30 days prior to screening. 7. Presence of known cardiovascular, metabolic, or renal disease or individuals with major signs or symptoms suggestive of cardiovascular, metabolic, or renal disease without medical clearance to participate in the exercise program. 8. Presence of any of the following laboratory abnormalities on screening labs: 1. Abnormal liver function (AST or ALT more than 2 times the upper limit of normal) 2. Abnormal renal function (creatinine clearance calculated by the Cockcroft-Gault equation \<50mL/min or estimated glomerular filtration rate using the MDRD4 equation or the CKD-EPI equation \<45mL/min/1.73m2) 3. Complete Blood Count out of range on screening labs and physician's judgment that abnormal value is clinically significant. 9. Uncontrolled hypertension (resting blood pressure \>150/90 mmHg). 10. Orthostatic hypotension and standing systolic BP below 100. Orthostatic hypotension is a reduction of systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg within 3 minutes of standing. 11. Already participating in 120 minutes or more of moderate intensity exercise per week. 12. Serious illness (requiring systemic treatment and/or hospitalization) within the last 4 weeks. 13. History of any other medical problem or injury that may interfere with ability to exercise. 14. Condition that precludes the safe performance of routine lumbar puncture, including: 1. INR \> 1.4 or other coagulopathy 2. Platelet cell count of \< 50,000/μL 3. Infection at the desired lumbar puncture site 4. Taking anti-coagulant medication within 90 days of baseline (Note: low dose aspirin is permitted) 5. Suspected non-communicating hydrocephalus or intracranial mass 6. Prohibitive lumbar spinal disease 15. Enrollment in another investigational study that includes an intervention; participation in non-interventional studies may be permitted 16. Receipt of any non-PD investigational product or device or participation in a non-PD drug research study within a period of 30 days (or 5 half-lives of the drug, whichever is longer) before baseline. 17. History of frequent falls (i.e. falling multiple times per week) or considered high fall risk based on investigator assessment 18. Lack of access to computer/tablet and WiFi or any other technical challenges that in the opinion of the investigator would prevent participation in the virtually supervised exercise training program.
Full study name & original research details

Official study title

Exercise for Cognitive Excellence in Parkinson's Disease

Original description

This study will evaluate the safety and feasibility of a home-based, virtually-supervised, combined high intensity endurance and resistance training program in people with Parkinson's disease. It will also evaluate the effects of exercise on cognition and underlying exercise-related biological markers (biomarkers).

Further description from the registry

Cognitive impairment begins early in Parkinson's disease (PD) and progresses to dementia in a majority of patients, impairing quality of life and contributing to growing health-related costs. Physical exercise has potent anti-aging effects and improves many outcomes in PD including cognition. Identifying biomarkers that respond to exercise, and how they associate with cognition and underlying disease pathology, may elucidate key mechanisms for countering cognitive decline. This is a randomized-controlled trial that evaluates safety and feasibility of a home-based exercise intervention in people with PD and measure its effects on cognition and circulating biomarkers of aging and stress. Thirty-two participants with PD will be randomized to receive a home-based, trainer-supervised endurance and resistance training program (exercise group) or no exercise (wait list control group) for 26 weeks. Cognitive assessments and patient reported outcomes will be obtained at baseline and at end of 26 weeks. Biomarkers in periphery (blood, saliva) and brain \[cerebrospinal fluid (CSF)\] will also be measured before and after the 26-week exercise intervention.

Conditions reported: Parkinson Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
Exercise; No Exercise
Phases
NA
Sponsor
University of California, San Francisco
Start date reported by registry
2023-07-20 (actual)

Registry updated: 2026-06-29 · Status last verified by the registry submitter: 2026-06

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

No central contact is listed. Check the location contacts or the official registry record.

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

University of California San Francisco

San Francisco, California, United States

Status not reported

Facility not reported

United States

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.